Economic burden of chronic lymphocytic leukemia in the era of oral targeted therapies in the United States

Journal of Clinical Oncology

Volumn 35, Issue 2, 2017, Pages 166-174

  Chen, Qiushi ^a,c   Jain, Nitin ^e   Ayer, Turgay ^a   Wierda, William G ^e   Flowers, Christopher R ^b   O'Brien, Susan M ^f   Keating, Michael J ^e   Kantarjian, Hagop M ^e   Chhatwal, Jagpreet ^c,d  

^a GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^b EMORY UNIVERSITY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; BENDAMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; IBRUTINIB; IDELALISIB; OBINUTUZUMAB; OFATUMUMAB; RITUXIMAB;

ADULT; AGED; ANEMIA; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITALIZATION COST; HUMAN; INFECTION; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MEDICARE; MOLECULARLY TARGETED THERAPY; NEUTROPENIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SIMULATION; SURVIVAL RATE; THROMBOCYTOPENIA; TIME TO TREATMENT; UNITED STATES; COST; COST OF ILLNESS; ECONOMICS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; THEORETICAL MODEL;

COST OF ILLNESS; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MODELS, THEORETICAL; QUALITY OF LIFE; UNITED STATES;

EID: 85009909925     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.68.2856     Document Type: Article

References (65)

1. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2015. CA Cancer J Clin 65:5-29, 2015
2. Jain N, O'Brien S: Initial treatment of CLL: Integrating biology and functional status. Blood 126: 463-470, 2015
3. Gribben JG, O'Brien S: Update on therapy of chronic lymphocytic leukemia. J Clin Oncol 29: 544-550, 2011
4. HallekM: Chronic lymphocytic leukemia: 2015 update on diagnosis, risk stratification, and treatment. Am J Hematol 90:446-460, 2015
5. Thompson PA, Tam CS, O'Brien SM, et al: Fludarabine, cyclophosphamide and rituximab achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood 127:303-309, 2016
6. Hallek M, Fischer K, Fingerle-Rowson G, et al: Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet 376:1164-1174, 2010
7. Keating MJ, O'Brien S, Albitar M, et al: Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23:4079-4088, 2005
8. Tam CS,O'Brien S,WierdaW, et al: Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112:975-980, 2008
9. Goede V, Fischer K, Busch R, et al: Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370:1101-1110, 2014
10. Byrd JC, Furman RR, Coutre SE, et al: Threeyear follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving singleagent ibrutinib. Blood 125:2497-2506, 2015
11. Brown JR, Byrd JC, Coutre SE, et al: Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110d, for relapsed/refractory chronic lymphocytic leukemia. Blood 123:3390-3397, 2014
12. Furman RR, Sharman JP, Coutre SE, et al: Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 370:997-1007, 2014
13. Jain N, O'Brien S: Targeted therapies for CLL: Practical issues with the changing treatment paradigm. Blood Rev 30:233-244, 2016
14. Food and Drug Administration: FDA approves new drug for chronic lymphocytic leukemia in patients with a specific chromosomal abnormality, 2016. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm495253.htm
15. Shanafelt TD, Borah BJ, Finnes HD, et al: Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels. J Oncol Pract11: 252-258, 2015
16. Yabroff KR, Dowling EC, Guy GP Jr, et al: Financial hardship associated with cancer in the United States: Findings from a population-based sample of adult cancer survivors. J Clin Oncol 34:259-267, 2016
17. SEER: Research Data (1973-2011), based on the November 2013 submission, in Surveillance Research Program SSB (ed), National Cancer Institute, DCCPS, 2014. http://seer.cancer.gov/data/citation.html
18. Hallek M, Fischer K, Fingerle-Rowson G, et al: Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet 376:1164-1174, 2010
19. Wierda WG, O'Brien S, Wang X, et al: Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J Clin Oncol 29: 4088-4095, 2011
20. Eichhorst BF, Busch R, Stilgenbauer S, et al: First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 114:3382-3391, 2009
21. Burger JA, Tedeschi A, Barr PM, et al: Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 373:2425-2437, 2015
22. Farooqui MZ, Valdez J, Martyr S, et al: Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: A phase 2, single-arm trial. Lancet Oncol 16: 169-176, 2015
23. Wierda W, O'Brien S, Wen S, et al: Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 23: 4070-4078, 2005
24. Fischer K, Cramer P, Busch R, et al: Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: A multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 29:3559-3566, 2011
25. Wierda WG, Kipps TJ, Mayer J, et al: Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 28:1749-1755, 2010
26. Byrd JC, Furman RR, Coutre SE, et al: Threeyear follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving singleagent ibrutinib. Blood 125:2437-2506, 2015
27. Khouri IF, Bassett R, Poindexter N, et al: Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: Long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome. Cancer 117:4679-4688, 2011
28. Majhail NS, Mau L-W, Denzen EM, et al: Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: A study using a large national private claims database. Bone Marrow Transplant 48:294-300, 2013
29. Khera N, Zeliadt SB, Lee SJ: Economics of hematopoietic cell transplantation. Blood 120: 1545-1551, 2012
30. Levinson DR:MedicaidDrug Price Comparison: Average Sales Price to Average Wholesale Price. Washington,DC,Office of the Inspector General, 2005
31. Arias E: United States life tables, 2010. Natl Vital Stat Rep 63:1-63, 2014
32. Byrd JC, Brown JR, O'Brien S, et al: Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 371:213-223, 2014
33. UpToDate: Drug informations, 2015. https://www.uptodate.com/
34. Maddocks KJ, Ruppert AS, Lozanski G, et al: Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol 1:80-87, 2015
35. Centers for Medicare & Medicaid Services: Medicare physician fee schedule, 2015. https://www.cms.gov/apps/physician-fee-schedule/overview.aspx
36. Parikh SA, Rabe KG, Kay NE, et al: Chronic lymphocytic leukemia in young (# 55 years) patients: A comprehensive analysis of prognostic factors and outcomes. Haematologica 99:140-147, 2014
37. Beusterien KM, Davies J, Leach M, et al: Population preference values for treatment outcomes in chronic lymphocytic leukaemia: A cross-sectional utility study. Health Qual Life Outcomes 8:50, 2010
38. Marsh K, Xu P, Orfanos P, et al: Model-based cost-effectiveness analyses for the treatment of chronic lymphocytic leukaemia: A review of methods to model disease outcomes and estimate utility. Pharmacoeconomics 32:981-993, 2014
39. Adena M, Houltram J, Mulligan SP, et al: Modelling the cost effectiveness of rituximab in chronic lymphocytic leukaemia in first-line therapy and following relapse. Pharmacoeconomics 32: 193-207, 2014
40. Guadagnolo BA, Punglia RS, Kuntz KM, et al: Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease. J Clin Oncol 24:4116-4122, 2006
41. Chen Q, Ayer T, Nastoupil LJ, et al: Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma. Value Health 18:189-197, 2015
42. Lee WC, Lamas GA, Balu S, et al: Direct treatment cost of atrial fibrillation in the elderly American population: A Medicare perspective. J Med Econ 11:281-298, 2008
43. Tumeh JW, Moore SG, Shapiro R, et al: Practical approach for using Medicare data to estimate costs for cost-effectiveness analysis. Expert Rev Pharmacoeconomics Outcomes Res 5:153-162, 2005
44. Ferguson J, Tolley K, Gilmour L, et al: PCN79 Health state preferences study mapping the change over the course of the disease process in chronic lymphocytic leukemia (CLL). Value Health 11:A485, 2008
45. Hanmer J, Lawrence WF, Anderson JP, et al: Report of nationally representative values for the noninstitutionalized US adult population for 7 healthrelated quality-of-life scores. Med Decis Making 26: 391-400, 2006
46. Catovsky D, Richards S, Matutes E, et al: Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): A randomised controlled trial. Lancet 370:230-239, 2007
47. Ortman JM, Velkoff VA, Hogan H: An Aging Nation: The Older Population in the United States. Washington, DC, US Census Bureau, 2014, p 25
48. The Henry J. Kaiser Family Foundation: The Medicare Part D PrescriptionDrug Benefit, 2016. http://kff.org/medicare/fact-sheet/the-medicare-prescription drug-benefit-fact-sheet
49. Congressional Budget Office: Prices for Brand-Name Drugs Under Selected Federal Programs. Washington, DC, The Congress of the United States, 2005. https://www.cbo.gov/sites/default/files/109th-congress-2005-2006/reports/06-16-prescriptdrug.pdf
50. Lafeuille M-H, Vekeman F, Wang S-T, et al: Lifetime costs to Medicare of providing care to patients with chronic lymphocytic leukemia. Leuk Lymphoma 53:1146-1154, 2012
51. Mariotto AB, Yabroff KR, Shao Y, et al: Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 103:117-128, 2011
52. The Kaiser Family Foundation; Health Research & Educational Trust:Employer Health Benefits Survey, 2014. http://files.kff.org/attachment/2014-employerhealth-benefits-survey-full-report
53. Himmelstein DU, Thorne D, Warren E, et al: Medical bankruptcy in the United States, 2007: Results of a national study. Am J Med 122:741-746, 2009
54. Kale HP, Carroll NV: Self-reported financial burden of cancer care and its effect on physical and mental health-related quality of life among US cancer survivors. Cancer 122:283-289, 2016
55. Ramsey SD, Bansal A, Fedorenko CR, et al: Financial insolvency as a risk factor for early mortality among patientswith cancer. J Clin Oncol 34:980-986, 2016
56. Kantarjian H, Steensma D, Rius Sanjuan J, et al: High cancer drug prices in the United States: Reasons and proposed solutions. J Oncol Pract 10: e208-e211, 2014
57. Light DW, Kantarjian H: Market spiral pricing of cancer drugs. Cancer 119:3900-3902, 2013
58. Chhatwal J, Mathisen M, Kantarjian H: Are high drug prices for hematologic malignancies justified? A critical analysis. Cancer 121:3372-3379, 2015
59. Goldstein DA, Ahmad BB, Chen Q, et al: Costeffectiveness analysis of regorafenib for metastatic colorectal cancer. J Clin Oncol 33:3727-3732, 2015
60. Goldstein DA, Chen Q, Ayer T, et al: First-and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: A United Statesbased cost-effectiveness analysis. J Clin Oncol 33: 1112-1118, 2015
61. Shih V, Ten Ham RM, Bui CT, et al: Targeted therapies compared to dacarbazine for treatment of BRAF(V600E) metastatic melanoma: A costeffectiveness analysis. J Skin Cancer 10.1155/2015/525302 [Epub ahead of print on June 10, 2015]
62. Meropol NJ, Schrag D, Smith TJ, et al: American Society of Clinical Oncology guidance statement: The cost of cancer care. J Clin Oncol 27: 3868-3874, 2009
63. Bach PB: Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med 360:626-633, 2009
64. Bach PB: New math on drug cost-effectiveness. N Engl J Med 373:1797-1799, 2015
65. Mahon F-X, Ré a D, Guilhot J, et al: Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11:1029-1035, 2010